Forward looking

Biosimilars and gene therapy: two shifts to plan for.

Over the next decade, healthcare will face two opposite pressures on drug spending: more competition for costly biologic drugs, and one-time gene therapies that cost millions per patient. Both are as much about logistics, payment, and trust as about science.

Biosimilar drugs

More competition for the most expensive medicines.

Biologic drugs are large, complex molecules made in living cells, and they account for a large share of drug spending. When their exclusivity ends, biosimilars can enter. They are highly similar to the original, not identical copies, and each is approved on its own evidence.

What a biosimilar is

A biologic shown to be highly similar to an approved reference product, with no clinically meaningful difference in safety or effectiveness. Living cells make biologics, so no two batches of any biologic are exactly alike. That is why biosimilars are not called generics.

How they are approved

In the US the pathway comes from the 2009 Biologics Price Competition and Innovation Act. The first US biosimilar was approved in 2015, and the EU approved its first in 2006. The FDA list now runs to roughly 90 products.

Interchangeability

In the US, a product designated interchangeable can be substituted at the pharmacy without the prescriber stepping in, subject to state law. Biosimilars of insulin glargine, denosumab, and aflibercept have received the designation. In the EU, approved biosimilars are considered interchangeable with their reference medicine.

Why it matters

Access and cost, if health systems manage the change well.

The FDA says biosimilar approvals can improve access by increasing the number of medication options and potentially lowering costs. Recent approvals include biosimilars of ranibizumab (Lucentis), rituximab (Rituxan), and insulin aspart (Novolog) in 2026.

Savings are not automatic. Uptake has varied widely depending on payer and pharmacy-benefit decisions, clinician confidence, and how contracts and rebates are structured.

What changes for health systems and payers

  • Formulary and switching policies, with clinician and pharmacist education
  • Contracting, where savings depend on rebates as well as list price
  • Inventory, expiry, and cold-chain tracking across more products
  • Monitoring of outcomes and adverse events after switches
  • Plain communication with patients, because trust is a real adoption barrier
Gene therapy

From one-time treatments for rare disease toward wider use.

Gene therapies treat disease at its genetic cause, often with a single treatment. The first approvals are for rare inherited conditions. The question for the next decade is how far, how safely, and at what price.

Where we are

The FDA licenses gene therapies for inherited eye disease (Luxturna, 2017), spinal muscular atrophy (Zolgensma, 2019), hemophilia, sickle cell disease, and other rare conditions. Casgevy, the first CRISPR-based therapy, was approved in the UK in November 2023 and in the US on 8 December 2023.

Two ways to deliver

Ex vivo: a patient’s cells are edited in a laboratory and returned, as with Casgevy. In vivo: a vector, often an adeno-associated virus or a lipid nanoparticle, carries the edit into the body.

The price and the risk

Launch list prices have ranged from about $2 million to $3.5 million per patient. Serious safety events have occurred with some therapies, so regulators expect long-term follow-up, often for many years.

What limits growth

  • Treatment capacity. Few qualified centers, and complex manufacturing and logistics.
  • Durability and immunity. Some vector-based therapies generally cannot be given twice.
  • Payment. A multi-million-dollar one-time cost is hard to budget. Outcomes-based and installment contracts, and a CMS model for sickle cell gene therapy, are early answers.
  • Access. Patients may need to travel to specialized centers.

What comes next

  • Newer editing methods. Base editing and prime editing, which change single letters of DNA without cutting both strands.
  • In vivo editing. Delivered by lipid nanoparticles, avoiding cell collection and conditioning treatment where it works.
  • Bespoke therapies. In 2025, clinicians reported a gene-editing treatment designed for one infant. If regulators and costs allow, this could scale.
  • Wider indications. More common conditions, if safety and price allow.
Getting ready

The hard parts are tracking, integration, and security.

A gene or cell therapy is made for one patient. That makes the supply chain unusually unforgiving, and it is where we help.

  • Chain of identity and custody. Every patient-specific product tracked from collection to infusion, with a complete audit trail. RFID and barcode tracking suit this.
  • Cold-chain monitoring. Temperature tracking for cryogenic and refrigerated products, including biosimilar biologics.
  • Data for long-term follow-up. Registries and records that outlast a single episode of care.
  • Genomic data security and consent. Sensitive data that needs strong protection and clear patient consent.
  • Financial risk planning. Budgeting for a few very costly patients without destabilizing the plan.
Planning horizon

What we expect, and how sure we are.

This is judgment, not prediction. Outlook as of 16 November 2026.

Now to 2028

Expansion and set-up

Biosimilar competition keeps spreading across immunology, eye care, and insulin. Health systems write switching policies. Gene therapy stays concentrated in specialist academic centers while payment models are tested.

2028 to 2031

Scale and competition

As exclusivity ends on more large oncology and immunology antibodies, we expect biosimilar competition to reach them. In vivo editing moves through clinical trials, and manufacturing and treatment capacity grow.

2031 to 2036

Possible normalization

Biosimilar-first prescribing may become the norm. Gene therapy could reach conditions more common than today's, if safety, durability, and cost allow. This is the least certain part of the outlook.

Questions to ask now

A short list for leadership teams.

Biosimilars

  • Do we have a clear switching policy, and who owns it?
  • How will we monitor outcomes after a switch?
  • Can we track inventory, expiry, and cold chain across more products?
  • How do rebates change the real cost of each option?

Gene therapy

  • Which therapies could our patients need in the next three years?
  • Are we, or a partner, a qualified treatment center?
  • How would we budget for a multi-million-dollar one-time treatment?
  • Can we prove chain of identity from collection to infusion?
Both shifts are less about the molecule than about logistics, payment, and trust.
Zada Partners

General information only, not clinical, legal, or financial advice. Product lists, prices, and regulations change; confirm current details with the FDA, the EMA, or your own advisers.

Planning for biosimilars or gene therapy?

Email info@zadapartners.com and tell us about your organization. We help with tracking, integration, and security.

Contact us